Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens reported selling 30,000 shares of common stock on August 4, 2026 at a weighted average price of $30.48 per share, with sale prices ranging from $30.25 to $30.88.

This transaction was effected under a Rule 10b5-1 trading plan, and she now directly holds 54,645 shares of Agios common stock.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares

Net Sell 1 txn

Insider Gheuens Sarah

Role Chief Medical Officer

Sold 30,000 shs ($914K)

Type	Security	Shares	Price	Value
Sale	Common stock F1, F2	30,000	$30.48	$914K

Holdings After Transaction: Common stock — 54,645 shares (Direct)

Footnotes (2)

1. F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 30,000 shares Weighted average sale price: $30.48 per share Sale price range: $30.25–$30.88 per share +2 more

5 metrics

Shares sold 30,000 shares Common stock sale on August 4, 2026 by Chief Medical Officer

Weighted average sale price $30.48 per share Average price for 30,000 shares of common stock sold

Sale price range $30.25–$30.88 per share Range of prices at which the reported shares were sold

Shares held after sale 54,645 shares Direct Agios common stock ownership by Sarah Gheuens after transaction

Sell transactions reported 1 transaction Number of non-derivative sale transactions in this insider report

Key Terms

Rule 10b5-1 trading plan, weighted average, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average financial

"The price reported is the weighted average of the shares sold."

A weighted average is a way of calculating an overall number when some items matter more than others by giving each item a different level of importance, or weight. Investors use weighted averages to combine figures like prices, returns or earnings so the result reflects the size or significance of each part — like grading a class where a final exam counts more than a quiz, producing a score that better represents true performance.

open market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 04:14 PM Accepted by SEC EDGAR 08/06/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What insider transaction did AGIO’s Chief Medical Officer report?

Chief Medical Officer Sarah Gheuens sold 30,000 shares of Agios common stock on August 4, 2026. The sale was reported as a non-derivative transaction coded “S,” indicating a sale in an open market or private transaction under a pre-arranged Rule 10b5-1 trading plan.

At what price were the AGIO shares sold by Sarah Gheuens?

Gheuens sold the shares at a weighted average price of $30.48 per share. According to the disclosure, the individual sale prices for the 30,000 shares ranged from $30.25 to $30.88, with full price breakdowns available upon request to the company or regulators.

How many AGIO shares does Sarah Gheuens hold after this sale?

After the reported transaction, Sarah Gheuens directly holds 54,645 shares of Agios common stock. This post-transaction holding reflects her remaining direct ownership following the sale of 30,000 shares in the open market or a private transaction on August 4, 2026.

Was the AGIO insider sale made under a Rule 10b5-1 trading plan?

Yes, the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Sarah Gheuens. Such trading plans allow insiders to pre-schedule trades, so the timing of these transactions is determined in advance rather than based on subsequent market or company developments.

What transaction code describes the AGIO insider sale by Sarah Gheuens?

The transaction is coded “S” for a sale of non-derivative common stock. The code description specifies it as a “Sale in open market or private transaction,” confirming that the reported 30,000-share disposition was a straightforward share sale rather than an option exercise or other derivative event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gheuens Sarah

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	08/04/2026		S(1)		30,000	D	$30.48(2)	54,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ William Cook, as attorney-in-fact for Sarah Gheuens	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)